Pall opens new Centre of Excellence in India

May 16, 2007 — EAST HILLS, NY — As part of its global initiative to align with customers worldwide, Pall Corporation today inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India. The center will drive process optimization innovations for the global life sciences market to meet the evolving opportunities and challenges of this fast-growing industry throughout Asia.

The new center includes a state-of-the-art proteomics laboratory to help customers speed the drug discovery process. It also houses a validation laboratory and a training facility with specialty experts to support Indian and regional customers as they increasingly enter the stringently regulated drug export market. India was strategically chosen as the location for Pall’s new Centre of Excellence in Asia because of the country’s highly regarded reputation in life sciences spanning biopharmaceutical research, development, and production.

Additionally, India’s diverse market opportunities coupled with a large pool of qualified scientists and engineers provide an ideal climate for fuelling innovation and growth. “Pall’s growth in the Asian life sciences market is a reflection of our focus on this important region and our continuing commitment to undertake several customer-centric initiatives there,” says Roberto Perez, president, Pall Life Sciences Worldwide. “The new Centre of Excellence will be instrumental in helping the life sciences industry in India and throughout the region apply the latest technologies and services to their operations, so they have the optimal tools and expertise to bring new and innovative drugs to market more efficiently.”

As Indian-based companies address the health care needs of their nation’s billion-plus population and also expand into the global marketplace, they constantly seek new approaches to broaden and improve their drug pipeline and their ability to produce them to a world-class standard. The new center will provide the pharmaceutical, biotechnology, and discovery markets throughout the region with a full range of total fluid management solutions to help them achieve their goals. Led by a highly specialized team of professionals, the new center joins other Pall Life Sciences Centres of Excellence throughout Europe and the Western Hemisphere in bringing together the latest technologies with process optimization knowledge and expertise.

With the opening of the center Pall Life Sciences also expands its customer technical support system. Customers anywhere in the world will be able to have immediate access (24 hours, 7 days a week) to Pall scientists and technical experts. “The success of our customers depends on their ability to carry out all stages of drug development — research, discovery and full-scale production — efficiently and cost-effectively,” says Vinay Joban, general manager, Pall BioPharmaceuticals India. “The new center provides the region with a complete range of services to support their operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements.”

The biopharmaceutical industry throughout Asia is experiencing a major surge in activity. The Indian pharmaceutical industry is one of the world’s largest, ranking 4th in terms of volume. According to Opportunities in Indian Pharma Sector (July 2006), India holds US$6 billion of the $550 billion global pharmaceutical industry, an annual increase of 10 percent compared with the 7 percent annual growth of the overall world market. The biotechnology market is also booming in India and is expected to continue on a fast pace with the support of the government through its comprehensive national biotechnology policy. Indian Biotechnology Market Outlook (February 2007) reports that the Indian biotechnology industry has grown 28.09 percent from 2005, and is likely to touch the US$5 billion mark by the end of 2010.

“Our new Centre of Excellence is the latest demonstration of Pall’s long-term commitment to grow and invest in Asia and align with our customers worldwide,” says Vinay Gupta, managing director and head of Pall Life Sciences in India. “It is key to our global strategy of working as a partner with the pharmaceutical and biotechnology industries and the academic research community to provide them with a full range of total process management solutions for improved optimization.”

About Pall in India and Asia
Pall Corporation has been present in India for more than two decades and was incorporated as Pall India in 1996. Headquartered in Mumbai, the company serves both life sciences and industrial markets where it provides total fluid management solutions for a broad range of critical applications to a diverse customer base. With staff strength of more than 200 people drawn from various disciplines and expertise, Pall continues to enhance and expand its operations in India. Currently, plans are underway to set up a new center in Pune to provide complete engineering solutions to the global market for Pall’s housings and systems portfolio. In addition to its operations in India, Pall serves the Asia-Pacific region with facilities in China, Indonesia, Japan, Korea, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.

About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: life sciences and industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, municipal and industrial water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2006 were $2.0 billion. The company headquarters is in East Hills, New York, with extensive operations throughout the world. For more information visit Pall at


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.